INTRODUCTION
Historically, before the 1990, the human fetus was considered as inhabiting a privileged environment where it was insulated from harm by the materno-placental unit 1 , but this paradigm is no longer accepted. Cohort studies with extended follow up of the offspring of mothers exposed to starvation during pregnancy, such as during the Dutch Famine 1,2 and the Leningrad Siege 3 , have demonstrated how this exposure was associated with both reduced birth weight and increased incidence of non-communicable diseases (NCD) or their physiological features 4 . A number of mechanisms have been proposed as explanations for associations between reduced fetal growth, as evidenced by reduced birth weight, and a broad spectrum of adult non-communicable diseases for which there is no cure including cardiovascular disease 5 , type II diabetes 6 , psychiatric diseases 7 , chronic renal failure 8 and polycystic ovarian disease 9 . These mechanisms include the thrifty phenotype 10 , the fetal origins hypothesis 5 , developmental plasticity 11 and predictive adaptive responses 12 and collectively fall under the concept of developmental origins of disease 4 (DOHaD). The thrifty phenotype and fetal origins hypotheses are focussed on fetal growth failure and predict that faltering fetal growth will be associated with adverse outcomes. The developmental plasticity and predictive adaptive responses theories would be less specific in predicting outcome but maintain that a single individual can achieve a number of phenotypes depending on the developmental milieu and that both fetal growth deceleration and acceleration may be beneficial or harmful to the individual depending on the postnatal environment.
Understanding the developmental mechanisms associated with faltering fetal growth and noncommunicable diseases will inform antenatal preventative interventions which will ultimately improve the health of the population and reduce burden on healthcare resources 13 . A major challenge to understanding fetal origins of non-communicable diseases in humans is measuring fetal well being. Fetal anthropometry, as evidenced by ultrasound measurement, has been used as an index of fetal well being and related to risk for outcomes in childhood. There is now emerging 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 obesity and hypertension and it is possible to determine whether the literature refutes or supports previous theoretical work. The present systematic review was designed to answer the question "are there consistent associations between antenatal size (e.g. small for gestational age) and faltering fetal growth and post natal outcomes?" The focus was on postnatal outcomes where DOHaD may be important and we set out to determine which of the different developmental theories best fitted the summation of the evidence identified.
METHOD

Search Methodology
The database search was carried out in July 2014 using OVID and also EMBASE and Google Scholar databases. The following terms were used for the search and were identified after reviewing relevant publications already known to the authors (also see online supplement for search strategy used): "Child", "Follow-up/Cohort/Epidemiological/Cross-sectional/Prospective Studies", "Fetal growth/development", "Infant/Infant New-born" and "Humans". Abstracts were reviewed independently by two researchers (FA and AE) and studies which potentially related antenatal fetal outcomes to postnatal outcomes identified. Eligible papers had to include fetal anthropometric ultrasound measurements representative of overall fetal size (i.e. crown rump length, biparietal diameter, head circumference, femur length, abdominal circumference and estimated fetal weight)
as the predictive variable and postnatal outcomes determined ≥1 week after birth as the outcome.
Studies which described outcomes of antenatal fetal congenital anomalies, eg echogenic bowel, congenital heart disease, cystic lesions in brain, lung and kidney, were not eligible since these fetal measurements were not representative of overall fetal size. Studies which related fetal measurements to perinatal outcomes (e.g. prematurity, increased/reduced birth weight and complications of delivery) or maternal exposures during pregnancy (e.g. maternal smoking or ambient air quality), were not eligible since our research question was focussed on the relationship 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Quality assessment
Quality assessment of all the included papers was carried out using a standard tool developed for use in any public health topic area (http://www.ephpp.ca/Tools.html). This process provides the reader with a global score as to the quality of evidence provided plus each study is rated over six domains (selection bias, study design, confounders, blinding, data collection methods and withdrawals and drop outs). Each domain is scored 1-3 and from these scores the global score is derived (1=strong study design, 2=moderate and 3=weak). Each paper was scored independently by two of the authors and a final score agreed.
RESULTS
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http://mc.manuscriptcentral.com/jech 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   C  o  n  f  i  d  e  n  t  i  a  l  :  F  o  r  R  e  v  i  e  w  O  n  l  y   7 The OVID search identified 450 study abstracts, 33 full texts were retrieved and 19 of these papers were ultimately included (see figure 1) . The EMBASE and Google scholar searches produced 36 and 4074 abstracts respectively, none of which yielded additional papers. A paper which described associations between antenatal and postnatal echocardiographic outcomes was not included 14 . Four further papers were identified from previously described cohort web sites. Of the 23 papers included in this review , 11 arose from the Generation R cohort, four from Southampton Women Survey (SWS), three from the Raine cohort, two from the Study of Eczema and Asthma To Observe the influence of Nutrition (SEATON) cohort and three from other studies. Only four studies presented results in children aged more than six years 16, [26] [27] [28] . All studies were from European or North American populations. Table 1 describes which fetal measurements were made in the five cohorts whose papers were included. Table 2 gives an overview of associations between small for gestational age and post natal outcome while table 3 describes associations between changing fetal size and postnatal outcomes. Table E1 on the on line data supplement presents fuller description of the study design and magnitude of the associations reported in individual papers. For each study, outcomes were first related to fetal size for a given gestation and then to fetal growth. Outcomes were categorised into: respiratory, allergy, obesity, neurodevelopmental, autistic spectrum disorders, febrile seizures, cardiovascular, renal and bone mineralisation. One of the studies achieved a strong global rating 15 , 12 received a moderate rating (most failed to gain strong rating by not demonstrating how non participation affected the population demographics) and the remainder were given a weak rating (most failed to gain moderate rating by not demonstrating whether/how confounders such as maternal smoking and socioeconomic status were considered), see online data supplement table E2. Of the 6 studies which found no evidence of association between small fetal size and post natal outcome, 4 were of poor quality study design 23, 3526 and 2 of moderate quality 17, 31 . Among the 4 studies which found no association between changing fetal size and outcomes, 3
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were of moderate quality design 21, 24, 31 and the fourth of poor quality 32 . 
Respiratory outcomes
There were four studies identified including two from the SEATON cohort. In the SEATON cohort, being small for gestational age(SGA) in the first trimester was associated with higher risk for doctor confirmed asthma and lower Forced Expiratory Volume in one second (FEV 1 ) at five 15 and ten years of age 16 . Second trimester SGA (here BPD was the measurement) was associated with higher asthma risk 15 at five and lower FEV 1 and Forced Expiratory Flow at 25-75% of Forced Vital Capacity(FEF ) at ten years 16 . Fetal measurements were not associated with bronchodilator response at five years, bronchial hyperreactivity at ten years, or exhaled nitric oxide at five or ten years. Growth acceleration between the first and second trimesters was associated with lower FEF at five and ten years but lower asthma risk at ten years compared with persistent high growth 15 . Growth acceleration between the first and second trimesters was also associated with lower risk for wheeze at three years of in the SWS 18 ; here children were stratified by skin prick positivity and increasing HC between 11 and 19 weeks was associated with lower risk for non-atopic wheeze. Increasing AC growth between 19 and 34 weeks was also associated with lower risk for atopic wheeze 18 . In the Generation R Cohort 17 there were no associations between fetal measurements or growth and respiratory outcomes at four years but postnatal weight gain was positively associated with risk for symptoms, regardless of antenatal size or growth.
Allergy outcomes
There were four papers identified. In the SEATON study, fetal size for a given gestation was not associated with risk for hayfever or eczema at ten years 16 (results not presented at five years) nor with skin prick reactivity five 15 or ten 16 years. When compared to persistent high growth, accelerated fetal growth size during first and second trimesters was associated with higher eczema risk and decelerating fetal growth with lower hay fever risk at ten years 16 . In SWS 18 , increasing AC growth between weeks 11 and 19 was also associated with higher risk for atopy but increasing AC growth between 19 and 34 weeks gestation was associated with decreased risk for atopy in three- 
Obesity
Obesity outcomes were reported in five studies, four from Generation R. In the Generation R Cohort, absolute measurements of second and third trimester EFW were not related to fat mass at age 6 months (calculated by dual-energy X-ray absorptiometry, DEXA) 20 but a relative increase in EFW z score of >0.67 was associated with higher fat mass. In a second paper from Generation R, SGA for third (but not second) trimester EFW was associated with an increase of borderline significance in ultrasound-determined abdominal fat deposits at age two years 21 ; the change in EFW between second and third trimesters was not associated with abdominal fat measurements 21 . In the third paper, first trimester CRL and second and third trimester FL and EFW were linked to peak velocities in height, weight and body mass index (BMI) up to four years of age 22 . There was no association between first trimester CRL and outcomes. There were positive associations between second (but not third) trimester EFW and peak weight velocity and FL and peak height velocity.
Second and third trimester EFW and relative growth between these times were all positively related to body mass index at adiposity peak. In the final paper from the Generation R cohort, first trimester size was related to total body fat at a median age of six years and each increase in z score in CRL was associated with a 0.3% reduction in total body fat [95% CI 0.03, 0.57] 36 . In the Project Viva cohort 19 , individuals in the highest quartile for EFW had higher BMI z score at three years and were at higher risk for obesity (defined as ≥95 th centile) when compared to the lowest quartile 19 . 
Neurodevelopment
There were three studies to consider neurodevelopment. One Generation R Cohort paper described associations between SGA for second and third trimester AC, EFW and ratio of AC:HC (but not HC per se) and higher risk for being in the lowest tertile for Touwen's Neurodevelopmental Examination at 9
to 15 weeks of age 24 . A second Generation R cohort publication related SGAfetal HC measurements in early, mid and late pregnancy to increased risk for delayed social development at twelve months, SGA HC in late pregnancy was also associated with increased risk for delays in self help and fine motor skills. Reduced relative size in HC between early and mid pregnancy (i.e. IUGR) was associated with higher risk for delayed fine motor development and SGA HC growth in later pregnancy with higher risk for delayed self-help abilities, gross and fine motor and language development at 12 months 25 . A case-control study from the Raine cohort related FL and HC at 18
weeks and HC at delivery to Specific Language Impairment 23 and there were no differences in fetal measurements between the 30 case and 30 controls. The prevalence of microcephaly (i.e. HC at birth <-1.67 z score) was higher among cases (40%) compared to controls (10%) 23 .
Autistic spectrum disorders (ASD)
There were three case-control studies. A study from the Raine cohort found no difference in head circumference at 18 weeks gestation and birth between 14 cases with ASD and 56 matched control 27 . A study from America 26 also found no difference in second trimester BPD, AC and FL between 45 cases and 222 controls. In a post hoc analysis, cases were subcategorised as multiplex autism (i.e. autism occurring in association with schizophrenic symptoms, n=8) or simplex autism (n=33); multiplex autism was associated with SGA AC compared with simplex autism and also with 28 . ASD risk was higher for the smallest and largest EFW, ie both small and large for gestational age. When individuals were subcategorised as ASD with or without intellectual disability, the associations with EFW were similar.
Febrile seizures
The Generation R cohort team related SGA second and third trimester fetal transverse cerebellar diameter [TCD] to risk for febrile seizures by two years of age 29 . There were 67 cases among the 3372 children studied. Individuals in the lowest tertile of third trimester EFW, AC and FL (but not HC) measurements were also at higher risk for febrile seizures compared to the highest tertile.
Cases had EFW similar to controls at 16 weeks gestation but by 34 weeks gestation, EFW was -0.4 z scores relatively lower for cases suggesting IUGR rather than SGA was important.
Cardiovascular Outcomes
Four reports considered cardiovascular outcomes. A study from the Raine Cohort related FL, AC and HC measured between 18 and 38 weeks gestation to systolic blood pressure (SBP) at age six years in 707 individuals 30 and observed an inverse association between FL and SBP. A similar finding was seem in the Generation R cohort where SGA FL at 30 (but not 20) weeks gestation was associated with increased SBP at age two years 31 . A second Generation R study reported a mean reduction in diastolic (but not systolic) blood pressure at six years of age of 0.43 mmHg [0.01, 0.84] for each z score increase in first trimester CRL but this association was not significant when the child's weight was considered 36 . In the project Viva cohort 19 , relative to individuals in the lowest quartiles for both EFW and birth weight, elevated SBP at three years was present among those who were (i) in the highest EFW quartile and second lowest birth weight quartile (ii) in the second lowest quartile for both and (iii) in the second lowest EFW quartile and second highest birth weight quartile. In the one paper identified, third (but not second) trimester HC and AC were positively associated with kidney volume at the age of 2 years 32 . There was no association between growth in HC and AC between second and third trimesters and kidney volume 32 .
Renal Outcomes
Bone mineralisation
There were four studies identified. In the first of three studies from the SWS, FL measurements at 19 and 34 weeks and growth between these gestations were positively associated with bone mineral content and skeletal size (expressed as bone area) in four year olds 33 ; bone outcomes were determined by whole-body DEXA scan. There were less convincing positive associations between AC and bone mineralisation. Femoral neck section modulus, an index of bending strength and relevant to fractures in the elderly, was determined in 493 six year olds in SWS and increasing FL growth between 19 and 34 weeks (and to a lesser degree between 11 and 19 weeks) was positively associated with this outcome 37 . In the second study, growth in FL and AC between the 11 th and 19 th weeks of pregnancy was positively associated with bone area and bone mineral content at birth and four years of age 34 . In the Generation R Study 35 , second and third trimester EFW were positively associated with bone mineral density (BMD) and content (BMC) in six month olds; some associations were only present for either lumbar spine only or total body BMD and BMC. Change in EFW between 20 and 30 weeks, but not between 30 weeks and term, were also positively associated with BMD for TB.
DISCUSSION
This is the first systematic review of the literature relating antenatal fetal size and growth to postnatal outcomes. We considered a broad spectrum of post natal outcomes since some organs pass through important developmental stages at the same gestation and an antenatal exposure at a given time might affect more than one organ. Equally, different organs develop at different gestations and serial fetal ultrasound measurements can give insight into the developmental origins of different health outcomes. The first main finding was that when associations were present, it was small for a given gestational age (and not large) that was linked to adverse outcomes with the exception of one study which found higher risk for autistic spectrum disorder among the smallest and largest second trimester fetuses 28 . The second notable finding was that growth deceleration was associated with some unfavourable outcomes although there were some inconsistencies between studies. The final important finding was that in utero growth acceleration was associated with adverse and beneficial outcomes (e.g. higher risk for asthma, obesity and atopy but also higher bone mineral density, environmental and socioeconomic influences may be present. We point out that causation cannot be implied from the associations we describe from the observational studies identified. The cohort members are still young, some of the associations described may resolve over time and it will be many years before follow up will be able to link fetal measurements to outcomes such as cardiovascular disease 5 and type II diabetes 6 .
Most studies found small for gestational age to be associated with a higher risk for "adverse" outcomes, and included birth weight and postnatal measurements in the analyses indicating that the "adverse outcomes" were not simply small fetuses becoming small infants and children. Inclusion of birth weight as a confounder does determine whether antenatal or neonatal measurement is more relevant to the outcome. Inclusion of birth weight might be a case of over adjustment since this birth weight is on any causal pathway between fetal measurements and post natal outcome and Developmental pauses at critical stages of development might explain these associations, for example the association between small for gestation and lower lung function was apparent from the first trimester 16 suggesting a problem in development occurring in very early pregnancy whereas associations with higher blood pressure were more apparent at 30 weeks gestation than at 20 weeks 30, 31 . During the embryonic and fetal periods, organs develop according to different timetables; for example in the lungs airway division occurs by 16 weeks gestation 38 whereas in the kidneys, glomerulogenesis occurs between 7 and 35 weeks gestation 39 . In this context, a transient exposure before 16 weeks might lead to a life-long aberration in airway function but not adversely affect renal function and the fetus will achieve a normal/near normal birth weight.
There was some consistency between studies for associations between change in fetal size and outcomes, for example (i) accelerated growth during early pregnancy associated with higher risk for eczema 16 and atopy 18 (ii) accelerated growth during later pregnancy associated with increased fat mass 20 , body mass index 22 and bone mineral density 33, 35 . There were also some apparent inconsistent associations between studies, for example (i) accelerated growth during late pregnancy and higher risk for eczema 17 but also lower risk for atopy 18 and hayfever 16 (ii) accelerating 19 and decelerating 19 growth during later pregnancy associated with higher systolic blood pressure or not at all 31 . These different outcomes may reflect differences in ages at postnatal assessment, different methodologies used to measure outcomes and differences between study populations. These different outcomes might also reflect genuine differences in determinants of antenatal growth in different populations.
The "fetal origins" hypothesis proposed that faltering growth during mid gestation was associated with higher risk for cardiovascular disease and we found evidence of faltering fetal growth being lower lung function and developmental delay. We also found evidence for increasing growth during early and late pregnancy being associated with higher risk for adverse outcomes in young children including lower lung function, increased asthma and adiposity (table 3) . Associations between relative acceleration and deceleration in growth and "advantageous" and "disadvantageous" There are a number of limitations to this review. First, there was considerable heterogeneity between study designs and meta analysis of data was not possible, furthermore outcomes measured within studies sometimes varied as the study participant became older, eg obesity and neurodevelopmental outcomes, and this limits direct comparison of results from the same cohort.
Second, gestational age certainty is crucial to the accurate interpretation of fetal measurements 40 and there is inevitable inaccuracy regardless of whether date of last menstrual period or first trimester fetal measurement is used (or combination of these), however this inaccuracy is not likely to alter the direction of any associations between fetal size and outcome within a population but is likely to reduce the true magnitude of any associations. A third factor to consider is that fetal measurements may not be an accurate index of fetal wellbeing, although the evidence from this review does support the role of fetal measurements as a surrogate for fetal wellbeing. Statistical points to note are that false positive results with borderline p values may have arisen due to multiple testing within studies and also due to post hoc analyses. Fourth, our quality control found that only one study had strong design; although blinding and data collection methods were strong, 41 and might offer a mechanism to alter antenatal growth.
In conclusion, this review of the literature has identified evidence that small fetal size and changes in fetal growth trajectory may be important to post natal outcomes. These associations do not prove causation but do suggest that antenatal interventions might be one option of preventing noncommunicable diseases in adulthood. The associations reported here require replication in nonWestern populations to confirm world-wide generalizability. Future research might look at intervention strategies aimed at preventing small for gestational age and growth failure but avoid stimulating fetal growth acceleration since this may lead to unwanted outcomes (table 2) . Outcomes with SGA not reported Generation R 17 No association with symptoms at 4yrs
Outcomes with SGA not reported Allergy SEATON 15, 16 No associations apparent between SGA and eczema, hayfever, skin prick reactivity or exhaled nitric oxide SWS 18 Outcomes with SGA not reported Generation R 17 Outcomes with SGA not reported Obesity Generation R [20] [21] [22] Not associated with peak growth velocities (PGV)
No relationship with EFW and fat mass at 6mo or abdominal fat mass (AFM) at 2 yrs. EFW associated with lowerweight PGV and body mass index at adiposity peak. FL inversely associated with height PGV.
No relationship with EFW and fat mass at 6mo but borderline association with AFM at 2 yrs and body mass index at adiposity peak Higher eczema risk at ten years 16 (CRL and BPD) Higher atopy at three years 18 (AC) Higher non atopic wheeze at three years 18 (HC)
Lower spirometry at ten years 16 (BPD and birth weight) Higher asthma risk at ten years 16 (BPD and birth weight) Lower hayfever risk at ten years 16 (BPD and birth weight)* Higher eczema risk at four years 17 (AC) Higher fat mass at six months 20 (EFW) Higher body mass index at adiposity peak 22 (EFW)
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Change from "small" to "large" between 1P First and second trimester fetal size and asthma outcomes at age ten years P 2 P SEATON 449 ten year olds Inverse association between CRL and asthma risk at ten years (6% [1, 11] risk reduction per mm). Positive association between CRL (increase 6ml [0, 11] per mm) and BPD (increase 21ml [9, 33] per mm) and FEVR 1 R at ten years.
Change from "small" to "large" between 1P 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 O n l y 
O n l y
Case-control studiesP 13-15 P were given a weak rating due to study design. Cohort studies other than SEATON were given a weak rating since evidence on the effect of drop outs was not presented. For selection bias, only the SEATON study presented details of mothers who did and did not participate (moderate rating), the remaining studies scored weak rating. The SEATON cohort received a weak rating for withdrawal and drop outs due to a <50% follow up at ten yearsP 2 P.
Blinding was assumed to be strong since the ultrasound measurements were made before postnatal outcomes were known. Data collection methods were all valid. O n l y O n l y 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 
